The investment company filed a lawsuit against the company in the District Court of New Jersey on Monday. T. Rowe Price claimed Valeant used a secret pharmacy network, deceptive pricing and reimbursement practices, and false accounting to protect the company’s drugs from generic competition and drive up revenues and profits. T. Rowe Price held a 6.4 percent stake in Valeant as of Dec. 31.
Valeant stock has lost almost 90 percent of its value since 2015 after the drug giant was tied to Philidor RX, a specialty pharmacy that allegedly used aggressive tactics to get insurers and pharmacy benefit managers to pay reimbursements for Valeant’s costly medications, reported The Wall Street Journal.
The lawsuit follows last week’s announcement that lawyers at the U.S. Attorney’s Manhattan, N.Y., office were investigating whether Valeant hid its relationship with Philidor from insurers.
More articles on supply chain:
Drug giants enter bidding war for cancer drugmaker
Medivation Limited access to pharmacies in rural Oregon linked to hospital readmission
Medtronic issues warning for heart valve delivery system following 19 deaths
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
